The Extracorporeal Membrane Oxygenation Systems Market was valued at US$ 690.05 Million in 2025 and is projected to reach US$ 1010.31 Million by 2033, registering a CAGR of 4.88% during 2026–2033.
The outlook combines expanding addressable demand with a need for disciplined execution across products, regions and channels. This version applies a balanced market structure and execution priorities lens while preserving BMI’s reported market values and conclusions. Extracorporeal Membrane Oxygenation (ECMO) is a crucial technology used for advanced life support in cases of severe cardiac or respiratory failure where traditional treatments have failed. ECMOs provide temporary assistance to the patient’s lungs and heart, which allows patients to stabilize while they recover in a high-acuity setting. Demand for ECMO is fueled by increased incidence of ARDS (acute respiratory distress syndrome), COPD (chronic obstructive pulmonary disease), heart failure, and complications from cardiac surgery.
Download Sample PDF @ https://www.businessmarketinsights.com/sample/BMIPUB00033220
What is driving the market?
The core growth engine is critical-care capacity; severe respiratory and cardiac failure; ECPR adoption; technology improvements. These forces expand demand because they change operating priorities and increase the value of solutions that improve performance, access, safety, efficiency or control. At the same time, the market is not frictionless: high treatment cost; specialized staffing; complication risk; infrastructure requirements. Suppliers that convert the strongest drivers into measurable customer outcomes while reducing adoption friction should be better positioned to capture the forecast expansion.
Which region leads?
Not publicly disclosed. Not publicly disclosed. BMI does not publish unsupported regional percentages in the public excerpt used here, so no share or CAGR is inferred. The practical implication is that geographic strategy should be based on verified local demand, infrastructure, regulation and channel maturity rather than on a fabricated ranking.
Which segment leads?
BMI identifies the following segment leadership or coverage: The public BMI excerpt covers pumps, oxygenators, controllers and cannulas across VV/VA/AV and respiratory/cardiac/ECPR use but does not disclose a numerical leading segment. Where the public page does not provide a numerical share, none is added. Commercially, these categories matter because they show where established demand, installed-base scale or application fit is strongest and where adjacent offerings can be positioned.
Which companies are prominent?
Prominent companies identified by BMI include Medtronic plc; Getinge AB (Maquet); LivaNova PLC; ABIOMED, Inc.; MicroPort Scientific Corporation; CytoSorbents Corporation; Spectrum Medical Ltd.; Hemovent GmbH; ALung Technologies, Inc.; OriGen Biomedical, Inc.; EUROSETS S.r.l.. Competition spans product development, partnerships, geographic reach, channel access and service capability. The list is not presented as a revenue ranking, and no market share is assigned unless BMI explicitly reports one.
What is changing in 2026?
For 2026, the verified development context is: The 2026 market remains focused on safer circuits, portability, monitoring and specialized critical-care capacity. This should be interpreted as evidence of the direction of the market, while broader commentary remains analytical rather than a claim that an undisclosed event has occurred.
What are the major investment opportunities?
The strongest commercial opportunities are portable ECMO; oxygenators and disposables; ECPR programs; specialty centers; training and monitoring services. These areas align most closely with the verified growth drivers and provide room for product, service and partnership revenue. Investors and operators should still test unit economics, qualification requirements, customer concentration and the constraints already identified before committing capital.
Explore the Extracorporeal Membrane Oxygenation Systems Market Snippet for a concise overview of the market landscape, evolving business applications, and key market trends shaping adoption across industries and regions. Understand the growth drivers and industry dynamics influencing market development and competitive positioning. Identify emerging opportunities and gain actionable insights to support strategic planning and informed decision-making.
Increasing Prevalence of Severe Cardiopulmonary Conditions
The increase in severe cardiopulmonary diseases requiring advanced life support has been the most important driver for the Extracorporeal Membrane Oxygenation (ECMO) Systems Market. Globally, there is an increase in the incidence of diseases such as: Acute Respiratory Distress Syndrome (ARDS), Heart Failure (HF), Chronic obstructive Pulmonary Disease (COPD), or Cardiac Complications due to Surgeries or Trauma, where the presence of these diseases mean that the patient must be treated with advanced Life Support – ECMO. The COVID-19 Pandemic was one of the main factors in increasing demand for ECMO, as the increase in patients with Severe Respiratory Failure resulted in a greater need to utilize/clinical reliance on ECMO. The increasing prevalence of the older population (Geriatric) population as well as the greater numbers of patients who survive complex cardiac surgeries, are also factors contributing to the increase in the patient population requiring ECMO. Increased awareness on the part of healthcare providers regarding the use of ECMO as either Bridge-to-Recovery or Bridge-to-Transplant has also been a key contributor to the establishment of additional ECMO programs in nations around the world. In addition, major advances in ECMO technologies have made these systems safer, easier to use, and therefore, have increased utilization within Intensive Care Units (ICUs). Thus, the rising burden of severe cardiopulmonary diseases continues to play a major role in enhancing the growth of the Global ECMO Systems Market.
Expansion into Portable and Mobile ECMO Applications
The ECMO systems market is expected to experience growth opportunity with the creation and implementation of portable, mobile and transportable ECMO equipment. The traditional sources of ECMO equipment were large and complex and were initially exclusively utilized within a hospital’s intensive care unit (ICU). However, advancements in technology have made it possible for ECMO devices to be smaller, lighter and user-friendly and used out of the hospital environment. As a result, critical care providers are now able to perform ECMO during transport to and from hospitals, during emergency transfer of patients in out-of-hospital settings, and in locations with limited access to resources.
Related Reading / Reports
- Critical Care Ventilators Market — This report covers an adjacent market with shared technology, end-use or value-chain drivers relevant to the primary market.
- Blood Gas Analyzer Market — The topic is directly relevant because it addresses a connected application, component or commercialization pathway.
- Blood Collection Market — This related market helps frame supplier, customer or technology dependencies that influence the primary market.
- Active Implantable Medical Devices Market — The report provides complementary context on an adjacent product or end-use area with clear commercial overlap.
Buy Report @ https://www.businessmarketinsights.com/buy/BMIPUB00033220
About Us
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact us:
If you have any questions about this report or would like further information, please contact us:
- Contact person: Ankit Mathur
- Email: [email protected]
- Phone: +16467917070
Press Release Source: Read the original article
